We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio
Read MoreHide Full Article
OPKO Health, Inc. (OPK - Free Report) is well poised for growth in the coming quarters, backed by its potential in Rayaldee. A robust second-quarter 2022 performance, along with a few strategic agreements, is expected to contribute further. Forex Woes and concerns regarding overdependence on Rayaldee persist.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 32.5% compared with 27.6% fall of the industry and 8.9% decline of the S&P 500.
The renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.89 billion. It projects 31.6% growth for 2023 and expects to maintain its strong performance. OPKO Health’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and broke even in the other, with the average earnings surprise being 33.3%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Potential in Rayaldee: We are upbeat about OPKO Health’s Rayaldee business. Within the Pharmaceuticals arm, revenues from products rose 0.6% in the second quarter of 2022, owing to higher RAYALDEE sales. Revenues from sales of RAYALDEE in the second quarter of 2022 were up 24% from the prior-year period.
In February, OPKO Health announced that Vifor Fresenius Medical Care Renal Pharma had initiated the commercial launch of RAYALDEE (extended-release calcifediol) in Germany, the first launch of RAYALDEE outside the United States.
Strategic Agreements: OPKO Health has entered into a slew of agreements over the past few months, raising our optimism. During the second quarter of 2022, management confirmed that BioReference Laboratories’ Scarlet Health announced a collaboration with Teladoc Health.
In May, it announced the acquisition of privately held biotechnology company, ModeX Therapeutics, Inc.
Strong Q2 Results: OPKO Health’s solid second-quarter 2022 results buoy our optimism. Uptick in year-over-year Pharmaceuticals revenues is encouraging. During the quarter, Pfizer Inc. launched OPKO Health’s NGENLA (Somatrogon) injection in Germany, Japan and additional global markets. Expansion of gross margin also bodes well. OPKO Health’s strength in its women's health and oncology businesses augur well. Robust adoption of the company’s digital health services buoys optimism.
Downsides
Forex Woes: OPKO Health derives a significant portion of its consolidated net revenues from international sales, which subjects the company to risks relating to fluctuations in currency exchange rates. The company, through its subsidiaries, operate in a wide variety of jurisdictions. Certain countries in which it operates or may operate have experienced geopolitical instability, economic problems and other uncertainties from time to time.
Overdependence on Rayaldee: OPKO Health’s Rayaldee is the company’s only pharmaceutical product approved for marketing in the United States. The company’s ability to generate revenues from product sales and achieve profitability is substantially dependent on its ability to effectively commercialize Rayaldee. Failure to successfully commercialize Rayaldee would have a material adverse effect on the company’s business, financial condition, cash flows and results of operations.
Estimate Trend
OPKO Health is witnessing a negative estimate revision trend for 2022. In the past 90 days, the Zacks Consensus Estimate for its earnings has widened from a loss of 21 cents per share to a loss of 38 cents.
The Zacks Consensus Estimate for the company’s third-quarter 2022 revenues is pegged at $187.3 million, suggesting a 51.5% fall from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Patterson Companies, Inc. (PDCO - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.
AMN Healthcare has lost 2.9% compared with the industry’s 32.3% fall in the past year.
Patterson Companies, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 7.9%. PDCO’s earnings surpassed estimates in all the trailing four quarters, the average beat being 16.5%.
Patterson Companies has gained 1.6% against the industry’s 9.4% fall over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 9.9%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.
McKesson has gained 83.7% against the industry’s 9.4% fall over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio
OPKO Health, Inc. (OPK - Free Report) is well poised for growth in the coming quarters, backed by its potential in Rayaldee. A robust second-quarter 2022 performance, along with a few strategic agreements, is expected to contribute further. Forex Woes and concerns regarding overdependence on Rayaldee persist.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 32.5% compared with 27.6% fall of the industry and 8.9% decline of the S&P 500.
The renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.89 billion. It projects 31.6% growth for 2023 and expects to maintain its strong performance. OPKO Health’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and broke even in the other, with the average earnings surprise being 33.3%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Potential in Rayaldee: We are upbeat about OPKO Health’s Rayaldee business. Within the Pharmaceuticals arm, revenues from products rose 0.6% in the second quarter of 2022, owing to higher RAYALDEE sales. Revenues from sales of RAYALDEE in the second quarter of 2022 were up 24% from the prior-year period.
In February, OPKO Health announced that Vifor Fresenius Medical Care Renal Pharma had initiated the commercial launch of RAYALDEE (extended-release calcifediol) in Germany, the first launch of RAYALDEE outside the United States.
Strategic Agreements: OPKO Health has entered into a slew of agreements over the past few months, raising our optimism. During the second quarter of 2022, management confirmed that BioReference Laboratories’ Scarlet Health announced a collaboration with Teladoc Health.
In May, it announced the acquisition of privately held biotechnology company, ModeX Therapeutics, Inc.
Strong Q2 Results: OPKO Health’s solid second-quarter 2022 results buoy our optimism. Uptick in year-over-year Pharmaceuticals revenues is encouraging. During the quarter, Pfizer Inc. launched OPKO Health’s NGENLA (Somatrogon) injection in Germany, Japan and additional global markets. Expansion of gross margin also bodes well. OPKO Health’s strength in its women's health and oncology businesses augur well. Robust adoption of the company’s digital health services buoys optimism.
Downsides
Forex Woes: OPKO Health derives a significant portion of its consolidated net revenues from international sales, which subjects the company to risks relating to fluctuations in currency exchange rates. The company, through its subsidiaries, operate in a wide variety of jurisdictions. Certain countries in which it operates or may operate have experienced geopolitical instability, economic problems and other uncertainties from time to time.
Overdependence on Rayaldee: OPKO Health’s Rayaldee is the company’s only pharmaceutical product approved for marketing in the United States. The company’s ability to generate revenues from product sales and achieve profitability is substantially dependent on its ability to effectively commercialize Rayaldee. Failure to successfully commercialize Rayaldee would have a material adverse effect on the company’s business, financial condition, cash flows and results of operations.
Estimate Trend
OPKO Health is witnessing a negative estimate revision trend for 2022. In the past 90 days, the Zacks Consensus Estimate for its earnings has widened from a loss of 21 cents per share to a loss of 38 cents.
The Zacks Consensus Estimate for the company’s third-quarter 2022 revenues is pegged at $187.3 million, suggesting a 51.5% fall from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Patterson Companies, Inc. (PDCO - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has lost 2.9% compared with the industry’s 32.3% fall in the past year.
Patterson Companies, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 7.9%. PDCO’s earnings surpassed estimates in all the trailing four quarters, the average beat being 16.5%.
Patterson Companies has gained 1.6% against the industry’s 9.4% fall over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 9.9%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.
McKesson has gained 83.7% against the industry’s 9.4% fall over the past year.